Sun Hang, Wang Yan, Sun Minghao, Ke Xindi, Li Changcan, Jin Bao, Pang Mingchang, Wang Yanan, Jiang Shangze, Du Liwei, Du Shunda, Zhong Shouxian, Zhao Haitao, Pang Yuan, Sun Yongliang, Yang Zhiying, Yang Huayu, Mao Yilei
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences (CAMS), Beijing, 100730, China; Liver Transplantation Center, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, 100730, China.
Eight-year MD Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
J Adv Res. 2024 Sep 14. doi: 10.1016/j.jare.2024.09.011.
Pancreatic cancer (PC) remains a challenging malignancy, and adjuvant chemotherapy is critical in improving patient survival post-surgery. However, the intrinsic heterogeneity of PC necessitates personalized treatment strategies, highlighting the need for reliable preclinical models.
This study aimed to develop novel patient-derived preclinical PC models using three-dimensional bioprinting (3DP) technology.
Patient-derived PC models were established using 3DP technology. Genomic and histological analyses were performed to characterize these models and compare them with corresponding patient tissues. Chemotherapeutic drug sensitivity tests were conducted on the PC 3DP models, and correlations with clinical outcomes were analyzed.
The study successfully established PC 3DP models with a modeling success rate of 86.96%. These models preserved genomic and histological features consistent with patient tissues. Drug sensitivity testing revealed significant heterogeneity among PC 3DP models, mirroring clinical variability, and potential correlations with clinical outcomes.
The PC 3DP models demonstrated their utility as reliable preclinical tools, retaining key genomic and histological characteristics. Importantly, drug sensitivity profiles in these models showed potential correlations with clinical outcomes, indicating their promise in customizing treatment strategies and predicting patient prognoses. Further validation with larger patient cohorts is warranted to confirm their potential clinical utility.
胰腺癌（PC）仍然是一种具有挑战性的恶性肿瘤，辅助化疗对于提高患者术后生存率至关重要。然而，胰腺癌的内在异质性需要个性化的治疗策略，这凸显了对可靠的临床前模型的需求。
本研究旨在利用三维生物打印（3DP）技术开发新型的患者来源的临床前胰腺癌模型。
使用3DP技术建立患者来源的胰腺癌模型。进行基因组和组织学分析以表征这些模型，并将它们与相应的患者组织进行比较。对胰腺癌3DP模型进行化疗药物敏感性测试，并分析与临床结果的相关性。
该研究成功建立了胰腺癌3DP模型，建模成功率为86.96%。这些模型保留了与患者组织一致的基因组和组织学特征。药物敏感性测试显示胰腺癌3DP模型之间存在显著异质性，反映了临床变异性以及与临床结果的潜在相关性。
胰腺癌3DP模型证明了其作为可靠的临床前工具的实用性，保留了关键的基因组和组织学特征。重要的是，这些模型中的药物敏感性概况显示出与临床结果的潜在相关性，表明它们在定制治疗策略和预测患者预后方面的前景。需要更大的患者队列进行进一步验证，以确认其潜在的临床实用性。
